reported that T2DM patients infected with COVID-19 using the DPP4 inhibitor had elevated lymphocyte counts, and their CRP and procalcitonin levels were decreased compared to those on conventional treatment (68), suggesting that the anti-inflammatory effect may restore the efficiency of the immune response after SARS-CoV-2 infection. This evidence concerns the gene DPP4 and COVID-19.